Active and clinically significant bacterial, fungal, or viral infection
Known active bacterial, viral, fungal, mycobacterial, or other infection
Ongoing treatment for systemic bacterial, fungal, or viral infection at Screening
Presence of fungal, bacterial, viral, or other infection requiring oral or IV antimicrobials for management within  days of first dose AMG 
Active and clinically significant bacterial, fungal, or viral infection
Active and clinically significant bacterial, fungal, or viral infection
Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within  days prior to the initiation of study drug.
Evidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal)
COHORT : Has an active uncontrolled infection requiring systemic therapy (viral, bacterial or fungal); patients with infection under active treatment and controlled with antibiotics are eligible
COHORT : Has an active uncontrolled infection requiring systemic therapy (viral, bacterial or fungal); patients with infection under active treatment and controlled with antibiotics are eligible
Symptomatic/active bacterial, or fungal, or any other opportunistic infection
Uncontrolled bacterial, viral or fungal infection in the  weeks before enrollment.
Known uncontrolled fungal, bacterial, and/or viral infection ?Grade .
Active bacterial, fungal or viral infection
Active bacterial, viral, or fungal infection requiring systemic therapy.
Systemic fungal, bacterial, viral or other infection that is not controlled.
Current active, uncontrolled bacterial, viral, or fungal infection
Active bacterial or viral infection
Evidence of an ongoing systemic bacterial, fungal, or viral infection.
Participants with active viral, bacterial or fungal infection requiring concurrent antiviral or antibiotics
Active >= grade  viral, bacterial, or fungal infection within  weeks prior to day  of protocol therapy
Active bacterial, fungal, or viral infection
Any clinically significant infection defined as any acute viral, bacterial, or fungal infection that requires specific treatment. NOTE: Anti-infective treatment must be completed ?  days prior to study registration.
Patients with active, uncontrolled bacterial, viral or fungal infection(s) requiring systemic therapy
PROCUREMENT EXCLUSION: Active bacterial fungal or viral infection
TREATMENT EXCLUSION: Active bacterial, viral or fungal infection
Systemic fungal, bacterial, viral or other infection that is not controlled
Participants receiving antibiotic therapy for treatment of a bacterial infection or bacterial prophylaxis upon admission for allogeneic HSCT; use of any agent (e.g. sulfamethoxazole/trimethoprim) for prophylaxis of pneumocystis jirovecii pneumonia is permitted; concurrent use of anti-fungal and anti-viral therapies is also permitted
Active, uncontrolled bacterial, viral, fungal, or other opportunistic infection requiring systemic therapy.
Active invasive fungal infection requiring treatment with anti-fungal medication
Active uncontrolled acute fungal, bacterial, or other infection that is unresponsive to therapy at time of study drug dosing
Exhibits evidence of other clinically significant uncontrolled condition(s), including, but not limited to: uncontrolled systemic infection (viral, bacterial, or fungal), diagnosis of fever and neutropenia within  week prior to first dose of study drug.
Active systemic viral, bacterial or fungal infection requiring treatment
Have an active fungal, bacterial, and/or known viral infection
Uncontrolled viral or bacterial infection at the time of study enrollment
AUTOLOGOUS APHERESIS: Severe intercurrent bacterial, viral or fungal infection
TREATMENT WITH SJCAR: Severe, uncontrolled bacterial, viral or fungal infection
Subjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or during day  (within  hrs of CAR T infusion)
Having any uncontrolled illness including ongoing or active bacterial, viral or fungal infection
Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal)
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management within  days of enrollment. Note: Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with sponsor.
Any active grade  or higher (per NCI CTCAE version .) viral, bacterial, or fungal infection within  weeks of the first dose of the study drug. Routine antimicrobial prophylaxis is permitted.
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
Participant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).
Active bacterial, fungal or viral infection.
Subjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis
Uncontrolled bacterial, viral or fungal infection in the  week before enrollment
Known uncontrolled fungal, bacterial, and/or viral infection ?Grade 
Uncontrolled active infection (bacterial, fungal, viral, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents
Absence of uncontrolled active infection (bacterial, fungal, viral, mycobacterial) not responding to treatment with antibiotics, antiviral agents, or antifungal agents
Active viral, bacterial, or fungal infection progressing on current treatment
Active bacterial, fungal or viral infection not controlled by adequate treatment, at enrollment.
have any clinically significant infection, defined as any acute viral, bacterial, or fungal infection that requires systemic treatment or have received any anti-infective treatment within  days prior to the screening visit;
Active bacterial, fungal or viral infection not controlled by adequate treatment, at enrollment
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Patients with uncontrolled systemic fungal, bacterial, viral or other infection are ineligible
Participant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management. Note: Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.
Ongoing or active infection (bacterial, fungal, or viral) of National Cancer Institute (NCI)-CTCAE version . grade > 
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous antimicrobials for management.
Uncontrolled systemic fungal, bacterial, viral, or other infection
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable; patients with fever thought to be likely secondary to leukemia are eligible; known hypersensitivity to any study drug
Documented fungal infection within  months of BMT
Active, uncontrolled bacterial, viral or fungal infection, requiring systemic therapy
Active bacterial, fungal or viral infection
Patients with uncontrolled active infection (viral, bacterial, and fungal) are not eligible
Active >= grade  (per NCI CTCAE v) viral, bacterial, or fungal infection within  weeks prior to initiation of study treatment
Does not have current uncontrolled bacterial, fungal, or viral infection
Uncontrolled active systemic infection (viral, bacterial, and fungal)
Acute bacterial, viral, or fungal infection requiring treatment at the time of registration
Uncontrolled active infection (bacterial, viral, fungal, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term treatment with oral agents
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Uncontrolled active infection (bacterial, viral, fungal, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term treatment with oral agents
EXCLUSION CRITERIA FOR TNBC: Uncontrolled active infection (bacterial, viral, fungal, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term treatment with oral agents
Active uncontrolled systemic fungal, bacterial or viral infection
Patient has active and uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
uncontrolled infection including evidence of ongoing systemic bacterial, fungal, or viral infection (excluding viral upper respiratory tract infections) at the time of initiation of study treatment;
Uncontrolled active systemic infection (viral, bacterial, and fungal)
Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV) , requiring treatment with intravenous (IV) antibiotic, IV anti-fungal, or anti-viral; (testing is not required for eligibility)
Uncontrolled viral, fungal, or bacterial infection
REGORAFENIB EXCLUSION CRITERIA: Known active infection (bacterial, fungal, viral); viral infection includes known HIV positivity, or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
ENTRECTINIB EXCLUSION CRITERIA: Known active infection (bacterial, fungal, viral including HIV positivity)
Active systemic fungal, bacterial, viral or other infection, unless disease is under treatment with antimicrobials and considered controlled in the opinion of the investigator
Active serious systemic disease, including active bacterial or fungal infection
Active viral, fungal, bacterial or other infection
Active fungal infection or bacterial sepsis
Patients should not have any uncontrolled illness including ongoing or active bacterial, viral or fungal infection
Patients must not have an uncontrolled bacterial, fungal or viral infection, defined as progressive symptoms despite therapy, at the time of the CD+ memory T-cell infusion; asymptomatic viremia is allowed
Patients with uncontrolled active infection (viral, bacterial, and fungal) are not eligible
Patients with documented active bacterial, viral or fungal infection, untreated systematic peptic ulcer disease, uncontrolled diabetes mellitus or serious concurrent medical disease that could limit survival to less than  months
PART : Uncontrolled viral or bacterial infection at the time of study enrollment
Patients with other conditions not related to CMV infection (e.g. uncontrolled bacterial sepsis or invasive fungal infection) which are also life-threatening and which would preclude evaluation of the effects of a T-cell infusion.
Active bacterial, viral, or fungal infection requiring systemic therapy or operative or radiological intervention.
An uncontrolled bacterial, viral, or fungal infection or an active duodenal ulcer, until these conditions are corrected or controlled.
Does not have current uncontrolled bacterial, fungal, or viral infection
Known mixed invasive mold fungal infection including Zygomycetes, and/or a known invasive Aspergillus fungal infection in which either study drug may not be considered active.
Active uncontrolled bacterial, viral, or fungal infection until these conditions are corrected or controlled
Patients with active viral, bacterial or systemic fungal infection requiring treatment.
Uncontrolled viral, bacterial or fungal infection
Patients with active uncontrolled life threatening infection (s) from viral, bacterial, fungal or other organisms will be excluded; patients with human immunodeficiency virus (HIV) infection will be excluded
Uncontrolled bacterial, mycobacterial, or fungal infection
Afebrile with clear chest imaging and no signs of active viral, bacterial, fungal infection unless determined to be, at the discretion of the investigator, not clinically significant in the context of this study
Active ongoing viral, bacterial, or fungal infection
Active viral, bacterial or fungal infection unless adequately treated; for fungal infection, patient should have completed full course of antifungal therapy with resolution of infection
Active viral, bacterial or fungal infection
Uncontrolled viral or bacterial infection at the time of study enrollment
Uncontrolled viral or bacterial infection at the time of study enrollment
Active fungal, bacterial, and/or viral infection.
Other serious uncontrolled conditions such as fungal, bacterial or viral infection; HIV, Hepatitis B or C, bleeding disorders, interstitial lung disease,
Clinically significant active viral, bacterial or fungal infection requiring:
Patients with known NCI CTCAE Grade  or higher (requiring IV antibiotics) active systemic or cutaneous viral, bacterial, or fungal infection.
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Active systemic fungal, bacterial, and/or viral infection.
Any active viral, bacterial, or systemic fungal infection within  weeks prior study entry
 Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management within  days of first dose AMG . NOTE: Simple UTI and uncomplicated bacterial pharyngitis are permitted after consultation with sponsor and if responding to active treatment.
Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or lisocabtagene maraleucel administration
Acute viral, bacterial, or fungal infection, which requires specific therapy. Acute therapy must have been completed at least  days prior to study treatment.
Uncontrolled active systemic fungal, bacterial, viral, or other infection or requirement for intravenous (IV) antibiotics
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management\r\n* Note: Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment
Uncontrolled viral or bacterial infection at the time of study enrollment
Participant had a serious infection within  weeks prior to randomization, including any Grade  or higher viral, bacterial, or fungal infection.
Clinically significant active viral, bacterial or fungal infection
Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy
Evidence of active viral, bacterial, or systemic fungal infection.
Patients with a systemic fungal, bacterial, viral, or other infection not controlled
Active bacterial, viral, or fungal infection
Serious concomitant disorder, including active bacterial, fungal, or viral infection, incompatible with the study (at the discretion of the principal investigator)
Current unresolved infection or history of chronic, active, clinically significant infection (viral, bacterial, fungal, or other) which, in the opinion of the Investigator, would preclude the patient from exposure to a biologic agent or pose a risk to patient safety
Any active grade  or higher (per NCI CTCAE version .) viral, bacterial, or fungal infection within  weeks of the first dose of the study drug. Routine antimicrobial prophylaxis is permitted.
Has an invasive fungal infection.
active bacterial, fungal infection, or detectable viral infection
Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ?  hours prior to infusion)
Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within four weeks of enrollment. Patients requiring any oral antiviral, fungal, or bacterial therapy must have completed treatment within one week of enrollment.
Uncontrolled acute life threatening bacterial, viral or fungal infection
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study drug
Uncontrolled systemic fungal, bacterial, or viral infection
Active bacterial, viral, or fungal infection requiring systemic treatment at the time of study entry.
Have active bacterial, fungal, and/or known viral infection.
Current or recent history (<  days prior to start of treatment) of a clinically significant bacterial, viral, fungal, parasitic or mycobacterial infection
Active bacterial infection
Active bacterial, viral, fungal, or other infection
Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous antibiotics
Progressive or persistent viral or bacterial infection
Active bacterial infection
Patients with a history of active systemic fungal infection.
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within  days of first study drug administration
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Have active bacterial or fungal infection (that is, requiring intravenous antibiotics at the time of initiating study treatment) and/or detectable viral infection.
Presence of known active bacterial, fungal, or viral infection requiring systemic therapy
Patients with uncontrolled active infection (viral, bacterial, and fungal) are not eligible
Has any clinically significant infection, i.e., any acute viral, bacterial, or fungal infection that requires specific treatment (anti-infective treatment has to be completed ?  days prior to study entry).
Any clinically significant infection defined as any acute viral, bacterial, or fungal infection that requires specific treatment. NOTE: Anti-infective treatment must be completed ?  days prior to study registration.
Participants with active bacterial, viral, or fungal infection requiring systemic treatment
Participant exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to: uncontrolled systemic infection requiring IV therapy (viral, bacterial or fungal).
Any history of current or within the past  hours of acute or chronic bacterial, fungal or viral infectious disease
Participants with active bacterial, viral, or fungal infection requiring systemic treatment within the last two months prior to registration
Have active bacterial or fungal infection, or detectable viral infection
Have an active infection of any kind (fungal, viral, or bacterial)
Other clinically significant uncontrolled condition(s) including, but not limited to, systemic infection (viral, bacterial or fungal)
Active and clinically significant bacterial, fungal, or viral infection
Systemic fungal, bacterial, viral, or other infection that is not controlled
Uncontrolled bacterial, viral or fungal infection
Active, uncontrolled bacterial, viral or fungal infection requiring systemic therapy.
Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Exhibits evidence of other clinically significant uncontrolled condition(s), including, but not limited to: uncontrolled systemic infection (viral, bacterial, or fungal), diagnosis of fever and neutropenia within  week prior to first dose of study drug
Active viral, bacterial or fungal infection
Uncontrolled viral or bacterial infection at the time of study enrollment
Any active systemic infection (viral, fungal, or bacterial) requiring active parenteral antibiotic therapy within  weeks of study drug administration.
Uncontrolled viral, bacteria or fungal infection at time of study enrollment
Active viral, bacterial or fungal infection
Any active systemic viral, bacterial, or fungal infection requiring IV treatment with antimicrobial therapy within  week prior to first dose
Active bacterial or viral infection
Active fungal, bacterial, and/or viral infection
Active viral, bacterial or fungal infection
Uncontrolled systemic bacterial, fungal or viral infection
The participant has active bacterial infection, fungal infection, or detectable viral infection or viral load.
Patients with other conditions not related to leukemic relapse (e.g. veno-occlusive disease or uncontrolled bacterial, viral or invasive fungal infection) which are also life-threatening and which would preclude evaluation of the effects of a T cell infusion
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Systemic fungal, bacterial, viral, or other infection that is not controlled, at the time of screening
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomization
Fungal or viral infection requiring additional therapy
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Have an active, known fungal, bacterial, and/or known viral infection.
Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Current uncontrolled bacterial, viral or fungal infection.
Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy at time of screening.
Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Have an active infection of any kind (fungal, viral, or bacterial)
Active and clinically significant bacterial, fungal, or viral infection
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy ?  days prior to administration of study medication
Active bacterial, fungal or viral infection.
Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Have an active, known fungal, bacterial, and/or known viral infection.
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment
Active symptomatic fungal, bacterial and/or viral infection including evidence of infection with HIV, HTL, positive serology for HCV or HBV (acute or chronic infection based on CDC guidelines)
Viral, bacterial, or fungal infection within  weeks prior to the first dose of treatment.
Evidence of uncontrolled systemic bacterial, fungal, or viral infection at the start of study drug
Active viral, bacterial or fungal infection requiring intravenous treatment with antimicrobial therapy starting less than four weeks prior to first dose.
Subject has serious/active bacterial, viral or fungal infection requiring systemic treatment.
Active bacterial, viral, or fungal infection
Does not have current uncontrolled bacterial, fungal, or viral infection
Patient has a current uncontrolled bacterial, fungal, or viral infection per the judgment of the principal investigator (PI)
Active and clinically significant bacterial, fungal or viral infection
History of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within  days
Active systemic fungal, bacterial, viral, or other infection, unless under treatment with anti-microbials and controlled/stable, as defined as being afebrile and hemodynamically stable for - hours
Active uncontrolled bacteria, fungal or viral infection
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Does not have current uncontrolled bacterial, fungal, or viral infection per the judgment of the principal investigator (PI)
Active bacterial infection
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
Patients with uncontrolled active infection (viral, bacterial, and fungal) are not eligible
Systemic infection requiring parenteral antibiotic therapy or other serious infection (bacterial, fungal, or viral) within  days before the first dose of study drug.
Evidence of any viral, bacterial, or fungal infection involving the lung and not responding to appropriate treatment
Active infection (symptomatic bacterial and fungal infection  newly diagnosed and/or requiring treatment)
Patients with a documented active infection prior to starting their preparative regimen; this includes grade  or higher viral, bacterial, or fungal infection
Patients with a documented active infection prior to starting their preparative regimen; this includes grade  or higher viral, bacterial, or fungal infection
Patients with a documented active infection prior to starting their preparative regimen; this includes grade  or higher viral, bacterial, or fungal infection
Patients with other conditions not related to CMV infection (e.g. uncontrolled bacterial sepsis or invasive fungal infection) which are also life-threatening and which would preclude evaluation of the effects of a T-cell infusion
Uncontrolled viral, bacterial, fungal or protozoal infection at the time of study enrollment
Patients with active or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Active acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy;
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within  days of first study drug administration
Uncontrolled bacterial, viral infection or invasive fungal infection
Active bacterial, viral, fungal infection not controlled with appropriate antimicrobial therapy
Subjects who are being treated for fungal, viral, or bacterial pneumonia
Uncontrolled bacterial, viral or fungal infection at the time of leukapheresis, lymphodepleting chemotherapy or JCAR infusion
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management.
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within  days prior to the initiation of study drug.
Invasive bacterial infection
Active serious systemic disease, including active bacterial or fungal infection within  weeks before study entry